Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis-Reference-Cited by-同舟云学术

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

Published:2021-01-01 Issue:1 Volume:157 Page:43
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Elewski Boni E.¹,Baddley John W.²,Deodhar Atul A.³,Magrey Marina⁴,Rich Phoebe A.⁵,Soriano Enrique R.⁶,Soung Jennifer⁷,Bao Weibin⁸,Keininger Dorothy⁹,Marfo Kwaku⁹,Patekar Manmath⁹,Sharma Abhishek¹⁰,Shete Abhijit⁹,Lebwohl Mark Gabriel¹¹

Affiliation:

1. University of Alabama at Birmingham, Department of Dermatology, Eye Foundation Hospital, Birmingham

2. Department of Medicine and Infectious Diseases, University of Alabama at Birmingham, Birmingham

3. Department of Rheumatology, Oregon Health & Science University, Portland

4. Department of Rheumatology, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, Ohio

5. Department of Dermatology, Oregon Health & Science Center, Portland

6. Sección Reumatología, Servicio de Clínica Médica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

7. Department of Dermatology, Southern California Dermatology and Harbor UCLA (University of California, Los Angeles), Santa Ana

8. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey

9. Novartis Pharma AG, Basel, Switzerland

10. Novartis Healthcare Pvt Ltd, Hyderabad, India

11. Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, New York

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2771083/jamadermatology_elewski_2020_oi_200052_1610466927.18173.pdf

Reference58 articles.

1. Latent tuberculosis infection: opportunities and challenges.;Chee;Respirology,2018

2. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling.;Houben;PLoS Med,2016

3. Active tuberculosis in patients with psoriasis receiving biologic therapy: a systematic review.;Snast;Am J Clin Dermatol,2019

4. AB1231?Incidence of tuberculosis with rheumatic diseases using TNF inhibitors: a systematic review.;Sartori;Ann Rheum Dis,2019

5. Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy.;Valesini;Clin Exp Rheumatol,2006

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of secukinumab in patients with chronic infections;JEADV Clinical Practice;2024-01-20

2. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis: lessons from treatment in adults and the way forward;Expert Review of Clinical Immunology;2024-01-08

3. Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events;Pharmaceuticals;2023-11-15

4. Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation;Dermatology;2023-11-14

5. A Propensity Score-Matched Study on the Changes of TB Status and TB-IGRA Values in Patients with Psoriasis with Latent TB Receiving Secukinumab;Dermatology and Therapy;2023-08-24